Skip to main content
. Author manuscript; available in PMC: 2022 Aug 12.
Published in final edited form as: Neuropsychopharmacology. 2022 Feb 9;47(10):1798–1807. doi: 10.1038/s41386-022-01283-8

Table 1. Demographic and self-reported substance use characteristics of the participants.

MORPHINE PLACEBO p value
N 40 40 ---
Age (years) 23.1 ± 3.1 23.9 ± 3.9 0.31
BMI (kg/m2) 21.4 ± 3.4 22.3 ± 2.7 0.19
Autism (AQ-k) 6.5 ± 3.8 5.7 ± 3.6 0.34
Anxiety (STAI) 38.1 ± 9.4 35.7 ± 8.3 0.23
Social Anxiety (LSAS) 36.7 ± 17.9 33.2 ± 19.0 0.39
Social Touch Preferences (STQ) 25.3 ± 9.5 27.1 ± 7.7 0.36
Alcohol use (%)a
    Never 7.5 7.5 ---
    Several times a year 25 30 ---
    Several times a month 42.5 35 ---
    1-2 times per week 22.5 27.5 ---
    3-4 times per week 2.5 0 ---
Tobacco use (%)b
    Not smoking 87.5 90 ---
    Occasionally (<10 cigarettes per week) 12.5 10 ---
Drug use (% lifetime – % last year)c
    Cannabis 47.5 – 25 60 – 32.5 ---
    Tranquilizers 7.5 – 5 5 – 2.5 ---
    Stimulants 25 – 10 17.5 – 7.5 ---
    Opiates 7.5 – 0 2.5 – 0 ---
    Hallucinogens 12.5 – 2.5 12.5 – 2.5 ---
    Other 5 – 2.5 2.5 – 0 ---
a

Self-report (“How often do you consume alcohol?”). Participants were excluded if they reported to consume alcohol more than 3-4 times per week and were screened for alcohol abuse/dependence using the Mini-International Neuropsychiatric Interview.

b

Self-report (“How often do you smoke cigarettes?”). Participants were excluded if they reported to smoke more than 10 cigarettes per week.

c

Self-report (“For each of the listed substances, please report if you have ever consumed the substance in your lifetime and/or if you have consumed it within the past year.”). Participants were excluded if they reported consumption of opiates within the past year and were screened for illicit substances regular use/abuse/dependence using the Mini-International Neuropsychiatric Interview.